Core Viewpoint - Wanbangde (002082.SZ) is advancing its differentiated MCR cyclic peptide new drug in the metabolism field and has obtained core patent authorization, while also developing new drug projects in the field of amyotrophic lateral sclerosis (ALS) [1] Group 1 - The company has made significant progress in the metabolism sector with the development of a differentiated MCR cyclic peptide new drug [1] - Core patent authorization has been successfully obtained for the new drug in the metabolism field [1] - In the ALS sector, the company is actively pursuing new drug research and development projects [1]